Biologic concentration testing in inflammatory bowel disease.

Area of Science:

• Gastroenterology
• Pharmacology
• Immunology

Background:

• Anti-tumor necrosis factor (anti-TNF) therapies have transformed inflammatory bowel disease (IBD) management.
• However, sustained efficacy is often limited by loss of response and suboptimal dosing.
• Serum drug concentrations correlate with clinical outcomes in IBD patients.

Purpose of the Study:

• To review anti-TNF pharmacokinetics and pharmacodynamics.
• To propose a rational approach for anti-TNF concentration testing in IBD.
• To highlight the benefits of proactive therapeutic drug monitoring.

Main Methods:

• Review of existing literature on anti-TNF pharmacokinetics and pharmacodynamics.
• Analysis of current clinical practices for anti-TNF monitoring.
• Discussion of proactive versus reactive monitoring strategies.

Main Results:

• Inadequate dose optimization contributes to the loss of durability in anti-TNF therapy.
• Therapeutic drug monitoring (TDM) can prevent immunogenicity and reduce rescue therapy needs.
• Proactive TDM may enhance the long-term durability of anti-TNF treatment.

Conclusions:

• Anti-TNF drug concentration testing is valuable in both reactive and proactive settings.
• Proactive monitoring with dose titration offers potential clinical benefits for IBD patients.
• Optimizing anti-TNF therapy through TDM can improve patient outcomes.